FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137367088> ?p ?o ?g. }

• W2137367088 endingPage "1942" @default.
• W2137367088 startingPage "1929" @default.
• W2137367088 abstract "Do high-risk patients who develop severe early ovarian hyperstimulation syndrome (OHSS) and receive low-dose GnRH antagonist in the luteal phase have lower live birth rates compared with high-risk patients who do not develop severe early OHSS and do not receive GnRH antagonist in the luteal phase?Low-dose luteal GnRH antagonist administration in women with severe early OHSS is associated with similar live birth rates to that of high-risk patients who do not develop severe early OHSS and do not receive GnRH antagonist in the luteal phase.It has been reported that luteal GnRH antagonist administration in patients with established severe early OHSS appears to prevent patient hospitalization and results in quick regression of the syndrome on an outpatient basis. However, the effect of such treatment on pregnancy outcome has been investigated in only a small number of animal studies.This is a prospective cohort study of 192 IVF patients who were at high risk for OHSS and who did not wish to cancel embryo transfer and have all embryos cryopreserved. The study was conducted between January 2009 and December 2011 at Eugonia Assisted Reproduction Unit.Patients were <40 years of age, with polycystic ovaries, at high risk for OHSS (defined by the presence of at least 20 follicles ≥11 mm on the day of triggering of final oocyte maturation) and not willing to cancel embryo transfer and cryopreserve all embryos, if severe early OHSS was diagnosed by Day 5 of embryo culture. Patients who were diagnosed with severe early OHSS on Day 5 post-oocyte retrieval were administered 0.25 mg of ganirelix for 3 days, from Day 5 until and including Day 7 (OHSS + antag group, n = 22). High-risk patients who did not develop the severe early OHSS did not receive GnRH antagonist in the luteal phase (control group, n = 172). All patients underwent embryo transfer on Day 5.Live birth rates (40.9 versus 43.6%), ongoing pregnancy rates (45.5 versus 48.8%), clinical pregnancy rates (50 versus 65.1%), positive hCG (72.7 versus 75%), duration of gestation (36.86 ± 0.90 weeks versus 36.88 ± 2.38 weeks) and neonatal weight (2392.73 ± 427.04 versus 2646.56 ± 655.74 g) were all similar in the OHSS + antag and control groups, respectively. The incidence of major congenital malformations was 2.9% (3/103) in children born in the control group compared with no cases (0/14) in children born following luteal GnRH antagonist administration. No stillbirths or intrauterine deaths, and no cases of pregnancy-induced late OHSS were recorded in either group. None of the 22 patients with severe early OHSS required hospitalization following luteal antagonist administration. Ovarian volume, ascites, hematocrit, white blood cell count, serum estradiol and progesterone decreased significantly (P < 0.001) by the end of the monitoring period (Day 11 post-oocyte retrieval), indicating rapid resolution of the severe OHSS.This is a prospective cohort investigation with a very limited number of patients receiving the intervention and a larger number of control patients. Our findings suggest that low-dose luteal GnRH antagonist administration during the peri-implantation period may be safe, although larger studies with follow-up of the children born are required.Our study suggests for the first time that low-dose luteal GnRH antagonist administration in women with severe early OHSS is associated with a favourable IVF outcome, comparable to control high-risk patients without severe OHSS and not receiving the intervention. Regarding the wider implications on the concept of an OHSS-free clinic, administration of GnRH antagonist in the luteal phase may present a tertiary management level in patients with established severe OHSS, along with the use of GnRH antagonist protocols for primary prevention and the replacement of hCG with GnRH agonist for triggering final oocyte maturation for secondary prevention. However, at present, fresh embryo transfer combined with antagonist administration should only be used with caution by experienced practitioners, after carefully deciding which patients can have a fresh transfer or embryo cryopreservation, until the current data are confirmed by larger trials." @default.
• W2137367088 created "2016-06-24" @default.
• W2137367088 creator A5012599511 @default.
• W2137367088 creator A5019981364 @default.
• W2137367088 creator A5025078412 @default.
• W2137367088 creator A5049774278 @default.
• W2137367088 creator A5071662033 @default.
• W2137367088 creator A5072948435 @default.
• W2137367088 creator A5085439899 @default.
• W2137367088 date "2013-04-26" @default.
• W2137367088 modified "2023-10-10" @default.
• W2137367088 title "Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS" @default.
• W2137367088 cites W141627978 @default.
• W2137367088 cites W157662192 @default.
• W2137367088 cites W1603023934 @default.
• W2137367088 cites W1964913259 @default.
• W2137367088 cites W1968490139 @default.
• W2137367088 cites W1970139299 @default.
• W2137367088 cites W1977002848 @default.
• W2137367088 cites W1977287353 @default.
• W2137367088 cites W1978597185 @default.
• W2137367088 cites W1980031812 @default.
• W2137367088 cites W1984054906 @default.
• W2137367088 cites W1987404568 @default.
• W2137367088 cites W1996215930 @default.
• W2137367088 cites W2004097736 @default.
• W2137367088 cites W2004662975 @default.
• W2137367088 cites W2008363246 @default.
• W2137367088 cites W2014713908 @default.
• W2137367088 cites W2017221906 @default.
• W2137367088 cites W2020946333 @default.
• W2137367088 cites W2021584960 @default.
• W2137367088 cites W2022003509 @default.
• W2137367088 cites W2022448263 @default.
• W2137367088 cites W2029331138 @default.
• W2137367088 cites W2035952021 @default.
• W2137367088 cites W2037397043 @default.
• W2137367088 cites W2037420362 @default.
• W2137367088 cites W2041726643 @default.
• W2137367088 cites W2041838883 @default.
• W2137367088 cites W2060427891 @default.
• W2137367088 cites W2063252447 @default.
• W2137367088 cites W2066195041 @default.
• W2137367088 cites W2070512684 @default.
• W2137367088 cites W2072699290 @default.
• W2137367088 cites W2074839511 @default.
• W2137367088 cites W2080194012 @default.
• W2137367088 cites W2081280082 @default.
• W2137367088 cites W2082023692 @default.
• W2137367088 cites W2085215264 @default.
• W2137367088 cites W2089386866 @default.
• W2137367088 cites W2095770951 @default.
• W2137367088 cites W2095812006 @default.
• W2137367088 cites W2098067089 @default.
• W2137367088 cites W2098645628 @default.
• W2137367088 cites W2101026206 @default.
• W2137367088 cites W2102156861 @default.
• W2137367088 cites W2102626152 @default.
• W2137367088 cites W2103393505 @default.
• W2137367088 cites W2104295025 @default.
• W2137367088 cites W2107529015 @default.
• W2137367088 cites W2113478419 @default.
• W2137367088 cites W2114201941 @default.
• W2137367088 cites W2114603482 @default.
• W2137367088 cites W2124263439 @default.
• W2137367088 cites W2124636437 @default.
• W2137367088 cites W2126893308 @default.
• W2137367088 cites W2135868809 @default.
• W2137367088 cites W2136216720 @default.
• W2137367088 cites W2139944110 @default.
• W2137367088 cites W2140780698 @default.
• W2137367088 cites W2141385816 @default.
• W2137367088 cites W2142544855 @default.
• W2137367088 cites W2143564115 @default.
• W2137367088 cites W2153711259 @default.
• W2137367088 cites W2156358718 @default.
• W2137367088 cites W2156909541 @default.
• W2137367088 cites W2158911427 @default.
• W2137367088 cites W2159529998 @default.
• W2137367088 cites W2159708861 @default.
• W2137367088 cites W2159789980 @default.
• W2137367088 cites W2161415649 @default.
• W2137367088 cites W2161828674 @default.
• W2137367088 cites W2165316591 @default.
• W2137367088 cites W2165672909 @default.
• W2137367088 cites W2167052091 @default.
• W2137367088 cites W2296000131 @default.
• W2137367088 cites W2312526211 @default.
• W2137367088 cites W2411954244 @default.
• W2137367088 cites W2418499473 @default.
• W2137367088 cites W2418551622 @default.
• W2137367088 cites W4251225149 @default.
• W2137367088 cites W4256605237 @default.
• W2137367088 doi "https://doi.org/10.1093/humrep/det114" @default.
• W2137367088 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23624582" @default.
• W2137367088 hasPublicationYear "2013" @default.
• W2137367088 type Work @default.
• W2137367088 sameAs 2137367088 @default.

• next